Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Information
Agency:
Department of Health and Human Services
Amount:
$713,733.00
Program:
SBIR
Contract:
4R44DK096706-02
Solitcitation Year:
2013
Solicitation Number:
PA11-096
Branch:
N/A
Award Year:
2013
Phase:
Phase II
Agency Tracking Number:
R44DK096706
Solicitation Topic Code:
NIDDK
Small Business Information
XERIS PHARMACEUTICALS, INC.
3208 Red River Street, Suite 300, Austin, TX, 78705-
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
609377135
Principal Investigator
 STEVEN PRESTRELSKI
 (858) 414-1014
 stevep@xerispharma.com
Business Contact
 YASH SABHARWAL
Phone: (512) 534-8340
Email: yash@xerispharma.com
Research Institution
 Stub
Abstract
DESCRIPTION (provided by applicant): The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of glucagon to the present insulin-based systems will allow greater control of blood glucose with a lower risk of hypoglycemia. The primary objective of the current proposal is directly relevant to an NIDDK research priority, the development of improved delivery systems for the artificial pancreas. This program intends to demonstrate the safety, pharmacokinetics and pharmacodynamics of this novel glucagon formulation in animals and in type 1 diabetics. The major clinical metric for thisstudy will be the capacity of this glucagon formulation to raise glucose levels even after short-term aging in a patch pump chamber. The initial effort of this project will develop and optimize a non-aqueous, liquid glucagon formulation designed for the bi-hormonal pump application, demonstrate its safety, and characterize its pharmacology in preclinical models. The second effort will take the optimized formulation into a clinical supplies manufacturing program. The manufacturing program will produce supplies for the clinical trial in a GMP facility and include shelf-life and 'in-use' stability testing. This effort also includes assessment of the safety, pharmacokinetics and preliminary efficacy (glucodynamics) of the non-aqueous, glucagon solution in a pumpsystem in a Phase 1 clinical trial in type 1 diabetics. PUBLIC HEALTH RELEVANCE The objective of this program is to further the development of a novel, stable, non-aqueous glucagon formulation as an integral component of a bi-hormonal (insulin-glucagon) pump system for treatment of persons with diabetes. The addition of a glucagon component to the present insulin-based systems will allow greater control of blood glucose with a lower risk of hypoglycemia.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government